scholarly journals KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

2019 ◽  
Vol 10 (4) ◽  
pp. 821-828 ◽  
Author(s):  
Xin-Hui Fu ◽  
Zhi-Ting Chen ◽  
Wen-Hui Wang ◽  
Xin-Juan Fan ◽  
Yan Huang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Adverse Prognostic Factor ◽  
Gastric Cancer Patients

PD-L1 as a prognostic factor in gastric cancer patients

2020 ◽  
Vol 46 (12) ◽  
pp. e10
Author(s):  
A. D''Ignazio ◽  
K. Polom ◽  
S. Qiujin ◽  
C. Williams ◽  
M. Guergova-- Kuras ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Gastric Cancer Patients

scholarly journals Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Niko Kemi ◽  
Maarit Eskuri ◽  
Joonas H. Kauppila
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Gastric Adenocarcinoma ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Tumour Stroma ◽  
Potential Prognostic Factor ◽  
Gastric Cancer Patients

Abstract Tumour-stroma ratio (TSR) is a novel potential prognostic factor in cancers and based on the proportions of stroma and tumour area. The prognostic value of TSR in gastric cancer is incompletely known. The aim of this study was to estimate prognostic significance of TSR in gastric adenocarcinoma. A search of PubMed (MEDLINE), Web of Science, EMBASE, Cochrane and Scopus databases was performed. A meta-analysis was conducted on five-year survival in gastric cancer patients using inverse variance random-effects methods. The literature search yielded 5329 potential titles, of which a total of seven studies were eligible. Results of six studies including a total of 1779 patients were pooled in the meta-analysis. Only 23 (1.3%) of the patients received neoadjuvant therapy. All six studies had a cut-off of 50% for the proportion of stroma when dividing the patients into low- and high stroma groups. Low TSR (high amount of stroma) was strongly associated with increased five-year mortality (hazard ratio 2.19, 95% CI 1.69–2.85). In conclusion, TSR is a strong prognostic factor in gastric cancer. It could be used to estimate prognosis of gastric cancer patients not receiving neoadjuvant chemotherapy. Further studies including patients receiving neoadjuvant therapy are recommended.

The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15191-e15191
Author(s):  
Sedef H. Aktas ◽  
Hakan Akbulut ◽  
Ozan Yazici ◽  
Nurullah Zengin ◽  
Nalan Akgun ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Marker ◽  
Vascular Endothelial ◽  
Gastric Cancer Patients ◽  
Endothelial Growth Factor

e15191 Background: Vascular endothelial growth factor (VEGF) is a key element stimulating the angiogenesis in solid tumors. In the current study, we aimed to assess the role of plasma VEGF levels as a prognostic and predictive marker for advanced gastric cancer patients treated with a modified docetaxel, cisplatinum and 5-florouracil (DCF) regimen. Methods: Thirty consecutive patients treated with a modified DCF regimen were included in the study. The plasma VEGF levels of the patients before treatment and following two cycles of chemotherapy were assayed. Results: The modified DCF regimen was well tolerated and yielded a median overall survival (OS) time of 9,0 months and 2-year OS rate of 20%. Good performance status, lower pre-treatment VEGF levels,and decrease in VEGF levels following chemotherapy were found to be independent prognostic factors for OS. Conclusions: The results of the current study suggest that the corrected plasma levels of VEGF could be used as a prognostic factor for advanced gastric cancer patients and a decrease in VEGF levels following 2 cycles of chemotherapy as a predictive marker for patients receiving DCF chemotherapy regimen.

Postoperative leukopenia as an independent prognostic factor in gastric cancer patients.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15076-e15076
Author(s):  
Xiaofeng Chen ◽  
Dong Pei ◽  
Oluf D. Røe ◽  
Jing Qian ◽  
Fang Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Independent Prognostic Factor ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document